Noncoding RNA Transcripts during Differentiation of Induced Pluripotent Stem Cells into Hepatocytes
Table 1
Gene ontology categories of differentially expressed miRNA targets (pathway union).
Comparison
KEGG pathway
value
#genes
#miRNAs
Upregulated miRNAs in HLC d24 compared to HLC d20
Fatty acid biosynthesis
0
1
2
ECM-receptor interaction
0
10
4
Fatty acid metabolism
5.984709e – 10
2
2
Proteoglycans in cancer
2.928118e − 09
31
3
Hippo signaling pathway
0.0001180971
13
3
Steroid biosynthesis
0.004048092
2
2
Adherens junction
0.01782237
11
2
Base excision repair
0.02708153
4
2
Upregulated miRNAs in HLC d20 compared to HLC d24
Lysine degradation
1.389225e − 08
9
2
Chronic myeloid leukemia
0.0001602018
13
2
Proteoglycans in cancer
0.0002270705
12
1
Wnt signaling pathway
0.0006146658
12
1
FoxO signaling pathway
0.003220974
18
2
Cell cycle
0.003295535
9
1
Pathways in cancer
0.004235095
17
1
Progesterone-mediated oocyte maturation
0.03364343
8
1
Oocyte meiosis
0.03398087
5
1
Signaling pathways regulating pluripotency of stem cells
0.05899564
9
1
Upregulated miRNAs in HLC d20 compared to hepatocytes
Fatty acid biosynthesis
0
4
4
ECM-receptor interaction
0
29
10
Lysine degradation
0
26
17
Proteoglycans in cancer
0
115
18
MicroRNAs in cancer
2.065015e − 14
55
3
Adherens junction
1.92849e − 10
56
14
Fatty acid metabolism
2.435736e − 07
12
5
Hippo signaling pathway
2.854731e − 07
76
15
Prion diseases
3.567319e − 07
2
1
Viral carcinogenesis
4.563306e − 07
90
10
Pathways in cancer
7.078609e − 05
155
11
Cell cycle
0.0002485214
62
9
p53 signaling pathway
0.02762094
42
10
Transcriptional misregulation in cancer
0.02815897
70
8
Upregulated miRNAs in hepatocytes compared to HLC d20
Fatty acid biosynthesis
0
4
7
ECM-receptor interaction
0
39
15
Lysine degradation
0
26
17
Cell cycle
0
92
17
Viral carcinogenesis
0
129
19
Hippo signaling pathway
0
92
23
Proteoglycans in cancer
0
140
23
Pathways in cancer
1.110223e − 16
235
20
Adherens junction
8.881784e – 16
59
20
Hepatitis B
3.774758e − 15
83
13
Chronic myeloid leukemia
3.940404e − 12
54
18
Colorectal cancer
3.432521e − 11
43
17
Glioma
9.944934e – 11
43
15
Fatty acid metabolism
1.771966e – 06
14
8
p53 signaling pathway
2.456315e – 06
47
16
Small cell lung cancer
8.452771e – 06
57
14
Oocyte meiosis
1.56543e − 05
65
12
Thyroid hormone signaling pathway
2.996244e – 05
64
11
Steroid biosynthesis
8.629469e – 05
7
12
Prostate cancer
0.0004910115
65
13
PI3K-Akt signaling pathway
0.001506451
118
10
Focal adhesion
0.001709285
81
9
TGF-beta signaling pathway
0.004683835
48
9
Upregulated miRNAs in HLC d24 compared to hepatocytes
Prion diseases
0
2
2
Fatty acid biosynthesis
0
4
6
Fatty acid metabolism
0
14
9
Proteoglycans in cancer
0
107
15
ECM-receptor interaction
0
34
18
Adherens junction
2.136489e – 10
52
16
Viral carcinogenesis
2.367215e – 07
84
11
Hippo signaling pathway
8.686167e – 05
76
14
Pathways in cancer
0.001098215
135
8
Lysine degradation
0.001337938
24
10
Transcriptional misregulation in cancer
0.003591186
53
7
p53 signaling pathway
0.04591601
39
11
Upregulated miRNA hepatocytes compared to HLC d24
Fatty acid biosynthesis
0
4
7
Hepatitis B
0
91
15
ECM-receptor interaction
0
41
16
Lysine degradation
0
27
18
Cell cycle
0
93
18
Viral carcinogenesis
0
132
18
Pathways in cancer
0
247
21
Hippo signaling pathway
0
91
22
Proteoglycans in cancer
0
143
23
Adherens junction
5.662137e – 15
58
19
Chronic myeloid leukemia
1.465494e – 14
58
19
Glioma
8.104628e – 14
46
16
Colorectal cancer
8.277157e – 12
45
18
p53 signaling pathway
2.698853e – 08
47
17
Oocyte meiosis
1.888721e – 07
67
13
Small cell lung cancer
5.78931e − 07
61
15
Thyroid hormone signaling pathway
1.055741e – 05
64
11
Prion diseases
2.777397e – 05
6
2
Steroid biosynthesis
4.649816e – 05
10
11
TGF-beta signaling pathway
6.111763e – 05
52
11
Prostate cancer
0.0001105553
66
13
Fatty acid metabolism
0.0001381028
13
7
PI3K-Akt signaling pathway
0.0001991286
138
11
FoxO signaling pathway
0.001107838
84
15
Focal adhesion
0.001779401
90
9
Bladder cancer
0.002833066
27
12
Melanoma
0.01182136
41
10
Protein processing in endoplasmic reticulum
0.01436954
105
12
Endocytosis
0.01445943
97
12
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
